Neuroepithelioma
Welcome,         Profile    Billing    Logout  
 292 Companies   371 Products   371 Products   177 Mechanisms of Action   18 Trials   3684 News 


«12345678910111213...7778»
  • ||||||||||  Yervoy (ipilimumab) / Ono Pharma, BMS
    Biomarker, Trial completion, Enrollment change, Trial primary completion date, IO biomarker:  Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma (clinicaltrials.gov) -  Dec 7, 2017   
    P1,  N=59, Completed, 
    Recruiting --> Completed | N=39 --> 26 | Trial primary completion date: Feb 2018 --> Aug 2017 Active, not recruiting --> Completed | N=28 --> 59 | Trial primary completion date: Nov 2017 --> Jul 2013
  • ||||||||||  Trial completion, Trial initiation date, Trial primary completion date:  Moletest Clinical Study in Scotland (clinicaltrials.gov) -  Dec 4, 2017   
    P=N/A,  N=1120, Completed, 
    Trial primary completion date: Sep 2016 --> Dec 2015 Not yet recruiting --> Completed | Initiation date: Aug 2014 --> Mar 2015 | Trial primary completion date: Aug 2014 --> Oct 2016
  • ||||||||||  Samcyprone (diphenylcyclopropenone) / Phio Pharma
    Trial completion, Enrollment change, IO biomarker:  Treatment of Cutaneous Metastases With Diphenylcyclopropenone (DPCP) (clinicaltrials.gov) -  Nov 29, 2017   
    P1,  N=6, Completed, 
    Not yet recruiting --> Completed | Initiation date: Aug 2014 --> Mar 2015 | Trial primary completion date: Aug 2014 --> Oct 2016 Active, not recruiting --> Completed | N=13 --> 6
  • ||||||||||  Enrollment change, Trial primary completion date:  Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas (clinicaltrials.gov) -  Nov 24, 2017   
    P1/2,  N=22, Active, not recruiting, 
    Active, not recruiting --> Completed | N=13 --> 6 N=30 --> 22 | Trial primary completion date: Feb 2014 --> Sep 2009
  • ||||||||||  Trial withdrawal:  A Vaccine Study for High Risk Cancers (clinicaltrials.gov) -  Nov 24, 2017   
    P1,  N=0, Withdrawn, 
    N=30 --> 22 | Trial primary completion date: Feb 2014 --> Sep 2009 Terminated --> Withdrawn
  • ||||||||||  PDC*mel / PDC line Pharma
    Trial completion, Enrollment change:  Safety Study of a Dendritic Cell-based Cancer Vaccine in Melanoma (clinicaltrials.gov) -  Nov 14, 2017   
    P1,  N=9, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed | N=15 --> 9
  • ||||||||||  SF1126 / SignalRx
    Trial primary completion date:  SF1126 for Patients With Relapsed or Refractory Neuroblastoma (clinicaltrials.gov) -  Nov 6, 2017   
    P1,  N=28, Recruiting, 
    Active, not recruiting --> Completed Trial primary completion date: Dec 2017 --> Dec 2018
  • ||||||||||  Imjudo (tremelimumab) / AstraZeneca, Pfizer
    Trial completion, Enrollment change, Trial initiation date, Trial primary completion date, Metastases:  Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma (clinicaltrials.gov) -  Oct 27, 2017   
    P2,  N=11, Completed, 
    Trial primary completion date: Jul 2017 --> Nov 2017 Active, not recruiting --> Completed | N=32 --> 11 | Initiation date: Jan 2010 --> Aug 2009 | Trial primary completion date: Jan 2013 --> Aug 2017
  • ||||||||||  doxazosin mesylate / Generic mfg.
    Trial primary completion date:  PRESCRIPT: Phenoxybenzamine Versus Doxazosin in PCC Patients (clinicaltrials.gov) -  Oct 26, 2017   
    P4,  N=134, Recruiting, 
    Active, not recruiting --> Completed | N=32 --> 11 | Initiation date: Jan 2010 --> Aug 2009 | Trial primary completion date: Jan 2013 --> Aug 2017 Trial primary completion date: May 2017 --> Dec 2017
  • ||||||||||  tasadenoturev (DNX-2401) / DNAtrix
    Trial completion:  D24GBM: Virus DNX2401 and Temozolomide in Recurrent Glioblastoma (clinicaltrials.gov) -  Oct 24, 2017   
    P1,  N=31, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed
  • ||||||||||  Phase classification:  Liver Transplantation and Uveal Malignant Melanoma (clinicaltrials.gov) -  Oct 20, 2017   
    P=N/A,  N=2, Completed, 
    Active, not recruiting --> Completed Phase classification: P2 --> P=N/A
  • ||||||||||  temozolomide / Generic mfg.
    Enrollment change, Trial termination:  FMISOPETSCS: FMISO-PET in Brain Tumors and SCS Effect (clinicaltrials.gov) -  Oct 19, 2017   
    P2,  N=6, Terminated, 
    Phase classification: P2 --> P=N/A N=20 --> 6 | Recruiting --> Terminated; Isotope (FMISO) production is no longer available in our country.
  • ||||||||||  lapatinib / Generic mfg.
    Biomarker, Trial completion:  GW572016 to Treat Recurrent Malignant Brain Tumors (clinicaltrials.gov) -  Oct 5, 2017   
    P2,  N=9, Completed, 
    Trial primary completion date: May 2017 --> Oct 2016 Recruiting --> Completed
  • ||||||||||  Azedra (iobenguane I 131) / Lantheus
    Phase classification, Trial initiation date:  N2007-01: Ultratrace (clinicaltrials.gov) -  Oct 4, 2017   
    P2a,  N=15, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: Feb 2016 --> Mar 2015 Phase classification: P2 --> P2a | Initiation date: Mar 2008 --> Jun 2008
  • ||||||||||  Inlyta (axitinib) / Pfizer
    Trial primary completion date:  A Study of Axitinib in Advanced Carcinoid Tumors (clinicaltrials.gov) -  Sep 27, 2017   
    P2,  N=30, Active, not recruiting, 
    N=40 --> 3 | Initiation date: Aug 1998 --> Dec 1996 | Active, not recruiting --> Terminated; slow accrual Trial primary completion date: Jun 2017 --> Jan 2017
  • ||||||||||  ADU-623 / Novartis
    Enrollment closed, Enrollment change:  Phase I Study of Safety and Immunogenicity of ADU-623 (clinicaltrials.gov) -  Sep 25, 2017   
    P1,  N=11, Active, not recruiting, 
    Recruiting --> Completed | Trial primary completion date: Dec 2018 --> Apr 2017 Recruiting --> Active, not recruiting | N=38 --> 11